medalphabetМедицинский алфавитMedical alphabet2078-56312949-2807ООО «Альфмед»10.33667/2078-5631-2021-6-41-47medalphabet-2006Research ArticleСтатьиСиндром раздраженного кишечника: что нового? (Обзор материалов UEG Week Virtual 2020)Irritable bowel syndrome: what's new? (UEG Week Virtual 2020 materials review)https://orcid.org/0000-0001-9370-4768ГаусО. В.GausO. V.

Гаус Ольга Владимировна, к.м.н., доцент кафедры факультетской терапии и гастроэнтерологии

Scopus Author ID: 56598554900

г. Омск

Gaus Olga V., PhD Med, associate prof. at Dept of Faculty Therapy and Gastroenterology

Scopus Author ID: 56598554900 

Omsk

gaus_olga@bk.ruhttps://orcid.org/0000-0002-6581-7017ЛивзанМ. А.LivzanM. A.

Ливзан Мария Анатольевна, д.м.н., проф., ректор, зав. кафедрой факультетской терапии и гастроэнтерологии

Scopus Author ID: 24341682600

г. Омск

Livzan Maria A., DM Sci, prof., rector, head of Dept of Faculty Therapy and Gastroenterology

Scopus Author ID: 24341682600 

Omsk

ФГБОУ ВО «Омский государственный медицинский университет» Минздрава РоссииРоссияOmsk State Medical UniversityRussian Federation20210706202116Практическая гастроэнтерология (1)4147Copyright © Гаус О.В., Ливзан М.А., 20212021Гаус О.В., Ливзан М.А.Gaus O.V., Livzan M.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-alphabet.com/jour/article/view/2006

Синдром раздраженного кишечника является крайне актуальной проблемой современной гастроэнтерологии, учитывая его высокую распространенность в популяции и значительное влияние на качество жизни пациентов. Более глубокое понимание этологии и патогенеза, многообразие разрабатываемых лекарственных препаратов для лечения СРК дают сегодня надежду на возможность эффективного контроля над заболеванием в обозримом будущем. В статье представлен краткий обзор последних достижений по изучению синдрома раздраженного кишечника, о которых было доложено на очередной Объединенной европейской гастронеделе (UEG Week Virtual 2020), прошедшей в октябре 2020 года.

Irritable bowel syndrome is a very urgent problem in modern gastroenterology. A deeper understanding of the ethology and pathogenesis, the variety of drugs for the treatment of IBS gives hope for the possibility of effective control over the disease in the near future. The article provides a brief overview of the latest advances in the study of irritable bowel syndrome, which were reported at the next UEG Week Virtual 2020, held in October 2020.

синдром раздраженного кишечникафункциональные расстройства пищеварительного трактаабдоминальная болькишечная микробиотаirritable bowel syndromefunctional disorders of the digestive tractabdominal painintestinal microbiotaГрант президента РФ для государственной поддержки молодых российских ученых– кандидатов наук МК-1679.2020.7 (соглашение № 075–15–2020–138 от 17.03.2020) «Разработка превентивной индивидуализированной стратегии ведения больных с синдромом раздраженного кишечника».Grant of the President of the Russian Federation for state support of young Russian scientists – candidates of sciences MK-1679.2020.7 (agreement No. 075–15–2020–138 dated 03.17.2020) ‘Development of a preventive individualized strategy for the management of patients with irritable bowel syndrome’.ReferencesFlacco M.E., Manzoli L., De Giorgio R., Gasbarrini A., Cicchetti A., Bravi F. et al. Costs of irritable bowel syndrome in European countries with universal healthcare coverage: a metaanalysis. Eur. Rev. Med. Pharmacol. Sci. 2019. Vol. 23, No. 7. P. 2986–3000.Flacco M.E., Manzoli L., De Giorgio R., Gasbarrini A., Cicchetti A., Bravi F. et al. Costs of irritable bowel syndrome in European countries with universal healthcare coverage: a metaanalysis. Eur. Rev. Med. Pharmacol. Sci. 2019. Vol. 23, No. 7. P. 2986–3000.Zhang F., Xiang W., Li C.Y., Li S.C. Economic burden of irritable bowel syndrome in China // World J. Gastroenterol. 2016. Vol. 22, No. 47. P. 10450–10460.Zhang F., Xiang W., Li C.Y., Li S.C. Economic burden of irritable bowel syndrome in China // World J. Gastroenterol. 2016. Vol. 22, No. 47. P. 10450–10460.Peery A.F., Crockett S.D., Murphy CC, et al. Burden and cost of gastrointestinal, liver, and pancreatic diseases in the United States: update 2018. Gastroenterology. 2019. Vol. 156, No. 1. P. 254–272.Peery A.F., Crockett S.D., Murphy CC, et al. Burden and cost of gastrointestinal, liver, and pancreatic diseases in the United States: update 2018. Gastroenterology. 2019. Vol. 156, No. 1. P. 254–272.Jabbar K.S., Dolan B., Eklund L., Wising C., Ermund A., Johansson A. et al. Association between Brachyspira and irritable bowel syndrome with diarrhoea. Gut. 2020. Vol. 0. P. 1–13.Jabbar K.S., Dolan B., Eklund L., Wising C., Ermund A., Johansson A. et al. Association between Brachyspira and irritable bowel syndrome with diarrhoea. Gut. 2020. Vol. 0. P. 1–13.Hampson DJ. The spirochete Brachyspira pilosicoli, enteric pathogen of animals and humans. Clin. Microbiol. Rev. 2018. Vol. 31, No. 1. e00087–17.Hampson DJ. The spirochete Brachyspira pilosicoli, enteric pathogen of animals and humans. Clin. Microbiol. Rev. 2018. Vol. 31, No. 1. e00087–17.Thorell K., Inganäs L., Backhans A., Agreus L., Ost A., Walker M.M. et al. Isolates from colonic spirochetosis in humans show high genomic divergence and potential pathogenic features but are not detected using standard primers for the human microbiota. J. Bacteriol. 2019. Vol. 201, No. 21. e00272–19.Thorell K., Inganäs L., Backhans A., Agreus L., Ost A., Walker M.M. et al. Isolates from colonic spirochetosis in humans show high genomic divergence and potential pathogenic features but are not detected using standard primers for the human microbiota. J. Bacteriol. 2019. Vol. 201, No. 21. e00272–19.Tsinganou E., Gebbers J.-O. Human intestinal spirochetosis a review. Ger. Med. Sci. 2010. Vol. 8. Doc 01.Tsinganou E., Gebbers J.-O. Human intestinal spirochetosis a review. Ger. Med. Sci. 2010. Vol. 8. Doc 01.Jandhyala S.M., Talukdar R., Subramanyam C., Vuyyuru H., Sasikala M., Reddy D.N. Role of the normal gut microbiota. World J. Gastroenterol. 2015. Vol. 21, No. 29. P. 8787–8803.Jandhyala S.M., Talukdar R., Subramanyam C., Vuyyuru H., Sasikala M., Reddy D.N. Role of the normal gut microbiota. World J. Gastroenterol. 2015. Vol. 21, No. 29. P. 8787–8803.Plasse T.F., Barton G., Davidson E., Abramson D., Kalfus I., Fathi R. et al. Bimodal Release Ondansetron Improves Stool Consistency and Symptomatology in Diarrhea-Predominant Irritable Bowel Syndrome: A Randomized, Double-Blind, Trial. Am.J. Gastroenterology. 2020. Vol 115, Issue 9. P. 1466–1473.Plasse T.F., Barton G., Davidson E., Abramson D., Kalfus I., Fathi R. et al. Bimodal Release Ondansetron Improves Stool Consistency and Symptomatology in Diarrhea-Predominant Irritable Bowel Syndrome: A Randomized, Double-Blind, Trial. Am.J. Gastroenterology. 2020. Vol 115, Issue 9. P. 1466–1473.Mawe G.M., Hoffman J.M. Serotonin signaling in the gastrointestinal tract; functions, dysfunctions, and therapeutic targets. Nat. Rev. Gastroenterol. Hepatol. 2013. Vol. 10, No. 8. P. 473–486.Mawe G.M., Hoffman J.M. Serotonin signaling in the gastrointestinal tract; functions, dysfunctions, and therapeutic targets. Nat. Rev. Gastroenterol. Hepatol. 2013. Vol. 10, No. 8. P. 473–486.Sayegh L., Paquette J.M., Essalihi R., Sicard E. Comparative bioavailability study of RHB-102 (24 mg ER tablets QD) versus ondansetron 8 mg trablets BID and a single dose of ondansetron 24 mg in healthy volunteers. Clin. Pharm. Ther. 2015. Vol. 97. S47. PI-092.Sayegh L., Paquette J.M., Essalihi R., Sicard E. Comparative bioavailability study of RHB-102 (24 mg ER tablets QD) versus ondansetron 8 mg trablets BID and a single dose of ondansetron 24 mg in healthy volunteers. Clin. Pharm. Ther. 2015. Vol. 97. S47. PI-092.US Food and Drug Administration. Zofran (ondansetron) Oral Formulation Approved Labeling. Режим доступа: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020103s036,020605s020,020781s020lbl.pdfUS Food and Drug Administration. Zofran (ondansetron) Oral Formulation Approved Labeling. Режим доступа: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020103s036,020605s020,020781s020lbl.pdfPique N., Gomez-Guille'n M.D.C., Montero M.P. Xyloglucan, a plant polymer with barrier protective properties over the mucous membranes: An overview. Int. J. Mol. Sci. 2018. Vol. 19. E673.Pique N., Gomez-Guille'n M.D.C., Montero M.P. Xyloglucan, a plant polymer with barrier protective properties over the mucous membranes: An overview. Int. J. Mol. Sci. 2018. Vol. 19. E673.Gnessi L., Bacarea V., Marusteri M., Pique N. Xyloglucan for the treatment of acute diarrhea: Results of a randomized, controlled, open-label, parallel group, multicentre, national clinical trial. BMC Gastroenterol. 2015. Vol. 15. P. 153.Gnessi L., Bacarea V., Marusteri M., Pique N. Xyloglucan for the treatment of acute diarrhea: Results of a randomized, controlled, open-label, parallel group, multicentre, national clinical trial. BMC Gastroenterol. 2015. Vol. 15. P. 153.Finegold S.M., Li Z., Summanen P.H., Downes J., Thames G., Corbett K. et al. Xylooligosaccharide increases bifidobacteria but not lac- tobacilli in human gut microbiota. Food Funct. 2014. Vol., No. 5. P. 436–445.Finegold S.M., Li Z., Summanen P.H., Downes J., Thames G., Corbett K. et al. Xylooligosaccharide increases bifidobacteria but not lac- tobacilli in human gut microbiota. Food Funct. 2014. Vol., No. 5. P. 436–445.Eutamene H., Placide F., Tondereau V., Theodorou V. Protective effect of mucoprotectants and prebiotic combination on gut barrier impairment and visceral hypersensitivity induced by an acute stress in rat. Gastroenterology. 2018. Vol. 154 (6), Suppl 1. S916.Eutamene H., Placide F., Tondereau V., Theodorou V. Protective effect of mucoprotectants and prebiotic combination on gut barrier impairment and visceral hypersensitivity induced by an acute stress in rat. Gastroenterology. 2018. Vol. 154 (6), Suppl 1. S916.Trifan A., Burta O., Tiuca N., Petrisor D.C., Lenghel A., Santos J. Efficacy and safety of Gelsectan for diarrhoea-predominant irritable bowel syndrome: A randomised, crossover clinical trial. United European Gastroenterology J. 2019. Vol. 7, No. 8. P. 1093–1101.Trifan A., Burta O., Tiuca N., Petrisor D.C., Lenghel A., Santos J. Efficacy and safety of Gelsectan for diarrhoea-predominant irritable bowel syndrome: A randomised, crossover clinical trial. United European Gastroenterology J. 2019. Vol. 7, No. 8. P. 1093–1101.Chey W.D., Lembo A.J., Rosenbaum D.P. Efficacy of Tenapanor in Treating Patients With Irritable Bowel Syndrome With Constipation: A 12-Week, Placebo-Controlled Phase 3 Trial (T3MPO-1). Am.J. Gastroenterol. 2020. Vol. 115, No. 2. P. 281–293.Chey W.D., Lembo A.J., Rosenbaum D.P. Efficacy of Tenapanor in Treating Patients With Irritable Bowel Syndrome With Constipation: A 12-Week, Placebo-Controlled Phase 3 Trial (T3MPO-1). Am.J. Gastroenterol. 2020. Vol. 115, No. 2. P. 281–293.Nakajima A., Seki M., Taniguchi S. Determining an optimal clinical dose of elobixibat, a novel inhibitor of the ileal bile acid transporter, in Japanese patients with chronic constipation: a phase II, multicenter, double-blind, placebo-controlled randomized clinical trial. J. Gastroenterol. 2018. Vol. 53, No. 4. P. 525–534.Nakajima A., Seki M., Taniguchi S. Determining an optimal clinical dose of elobixibat, a novel inhibitor of the ileal bile acid transporter, in Japanese patients with chronic constipation: a phase II, multicenter, double-blind, placebo-controlled randomized clinical trial. J. Gastroenterol. 2018. Vol. 53, No. 4. P. 525–534.Nakajima A., Seki M., Taniguchi S., Ohta A., Gillberg P.G., Mattsson J.P. et al. Safety and efficacy of elobixibat for chronic constipation: results from a randomised, double- blind, placebo-controlled, phase 3 trial and an open-label, single-arm, phase 3 trial. Lancet Gastroenterol Hepatol. 2018. Vol. 3, No. 8. P. 537–547.Nakajima A., Seki M., Taniguchi S., Ohta A., Gillberg P.G., Mattsson J.P. et al. Safety and efficacy of elobixibat for chronic constipation: results from a randomised, double- blind, placebo-controlled, phase 3 trial and an open-label, single-arm, phase 3 trial. Lancet Gastroenterol Hepatol. 2018. Vol. 3, No. 8. P. 537–547.Nakajima A., Taniguchi S., Kurosu S., Gillberg P.G., Mattsson J.P., Camilleri M. Efficacy, long-term safety, and impact on quality of life of elobixibat in more severe constipation: Post hoc analyses of two phase 3 trials in Japan. Neurogastroenterol. Motil. 2019. Vol. 31, No. 5. e13571.Nakajima A., Taniguchi S., Kurosu S., Gillberg P.G., Mattsson J.P., Camilleri M. Efficacy, long-term safety, and impact on quality of life of elobixibat in more severe constipation: Post hoc analyses of two phase 3 trials in Japan. Neurogastroenterol. Motil. 2019. Vol. 31, No. 5. e13571.Brenner D.M., Fogel R., Dorn S.D., Krause R., Eng P., Krishoff R. et al. Efficacy, safety, and tolerability of plecanatide in patients with irritable bowel syndrome with constipation: Results of two phase 3 randomized clinical trials. Am.J. Gastroenterol. 2018. Vol. 113, No. 5. P. 735–745.Brenner D.M., Fogel R., Dorn S.D., Krause R., Eng P., Krishoff R. et al. Efficacy, safety, and tolerability of plecanatide in patients with irritable bowel syndrome with constipation: Results of two phase 3 randomized clinical trials. Am.J. Gastroenterol. 2018. Vol. 113, No. 5. P. 735–745.Ливзан М.А. Болевой синдром в гастроэнтерологии алгоритм терапии. Медицинский совет. 2010. № 3–4. С. 69–71. Livzan M.A. Pain syndrome in gastroenterology therapy algorithm. Medical advice. 2010. No. 3–4. S. 69–71.Ливзан М.А. Болевой синдром в гастроэнтерологии алгоритм терапии. Медицинский совет. 2010. № 3–4. С. 69–71. Livzan M.A. Pain syndrome in gastroenterology therapy algorithm. Medical advice. 2010. No. 3–4. S. 69–71.Ахмедов В.А., Орлов И.Н., Гаус О.В. Современные методы реабилитации пациентов с синдромом раздраженного кишечника. Терапия. 2017. № 3 (13). С. 49–55. Akhmedov V.A., Orlov I.N., Gaus O.V. Modern methods of rehabilitation of patients with irritable bowel syndrome. Therapy. 2017. No. 3 (13). S. 49–55.Ахмедов В.А., Орлов И.Н., Гаус О.В. Современные методы реабилитации пациентов с синдромом раздраженного кишечника. Терапия. 2017. № 3 (13). С. 49–55. Akhmedov V.A., Orlov I.N., Gaus O.V. Modern methods of rehabilitation of patients with irritable bowel syndrome. Therapy. 2017. No. 3 (13). S. 49–55.Ливзан М.А., Гаус О.В., Турчанинов Д.В., Попелло Д.В. Синдром абдоминальной боли в молодежной среде: распространенность и факторы риска. Экспериментальная и клиническая гастроэнтерология. 2019. Т. 170, № 10. С. 12–17. Livzan M.A., Gaus O.V., Turchaninov D.V., Popello D.V. Abdominal pain syndrome among youth: prevalence and risk factors. Experimental and Clinical Gastroenterology. 2019.Vol. 170, No. 10, pp. 12–17.Ливзан М.А., Гаус О.В., Турчанинов Д.В., Попелло Д.В. Синдром абдоминальной боли в молодежной среде: распространенность и факторы риска. Экспериментальная и клиническая гастроэнтерология. 2019. Т. 170, № 10. С. 12–17. Livzan M.A., Gaus O.V., Turchaninov D.V., Popello D.V. Abdominal pain syndrome among youth: prevalence and risk factors. Experimental and Clinical Gastroenterology. 2019.Vol. 170, No. 10, pp. 12–17.Weerts Z. Z.R.M., Masclee A. A.M., Writteman B. J.M., Clemens C. H.M., Winkens B., Brouwers J.R.B.J. et al. Efficacy and Safety of Peppermint Oil in a Randomized, Double-Blind Trial of Patients With Irritable Bowel Syndrome. Gastroenterology. 2020. Vol. 158, Issue 1. P. 123–136.Weerts Z. Z.R.M., Masclee A. A.M., Writteman B. J.M., Clemens C. H.M., Winkens B., Brouwers J.R.B.J. et al. Efficacy and Safety of Peppermint Oil in a Randomized, Double-Blind Trial of Patients With Irritable Bowel Syndrome. Gastroenterology. 2020. Vol. 158, Issue 1. P. 123–136.Wood J.D. Neuropathophysiology of irritable bowel syndrome. J. Clin. Gastroenterol. 2002. Vol. 35, suppl 1. S11–S22.Wood J.D. Neuropathophysiology of irritable bowel syndrome. J. Clin. Gastroenterol. 2002. Vol. 35, suppl 1. S11–S22.Barbara G., Stanghellini V., De Giorgio R., Cremon C., Cottrell G. S., Santini D. et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology. 2004. Vol. 126. P. 693–702.Barbara G., Stanghellini V., De Giorgio R., Cremon C., Cottrell G. S., Santini D. et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology. 2004. Vol. 126. P. 693–702.La J.H., Kim T.W., Sung T.S., Kim H.J., Kim J.Y., Yang I.S. Role of mucosal mast cells in visceral hypersensitivity in a rat model of irritable bowel syndrome. J. Vet. Sci. 2004. Vol. 5, No. 4. P. 319–324.La J.H., Kim T.W., Sung T.S., Kim H.J., Kim J.Y., Yang I.S. Role of mucosal mast cells in visceral hypersensitivity in a rat model of irritable bowel syndrome. J. Vet. Sci. 2004. Vol. 5, No. 4. P. 319–324.Костенко М.Б., Ливзан М.А. Механизмы развития синдрома раздраженного кишечника. Сибирский журнал гастроэнтерологии и гепатологии. 2000. № 10. С. 32. Kostenko M.B., Livzan M.A. Irritable bowel syndrome development mechanisms. Siberian Journal of Gastroenterology and Hepatology. 2000. No. 10. P. 32.Костенко М.Б., Ливзан М.А. Механизмы развития синдрома раздраженного кишечника. Сибирский журнал гастроэнтерологии и гепатологии. 2000. № 10. С. 32. Kostenko M.B., Livzan M.A. Irritable bowel syndrome development mechanisms. Siberian Journal of Gastroenterology and Hepatology. 2000. No. 10. P. 32.Wouters M.M., Balemans D., Van Wanrooy S., Dooley J., Gibert-Goton V., Alpizar Y.A. et al. Histamine receptor H1mediated sensitization of TRPV1 mediates visceral hypersensitivity and symptoms in patients with irritable bowel syndrome. Gastroenterology. 2016. Vol. 150. P. 875–887.Wouters M.M., Balemans D., Van Wanrooy S., Dooley J., Gibert-Goton V., Alpizar Y.A. et al. Histamine receptor H1mediated sensitization of TRPV1 mediates visceral hypersensitivity and symptoms in patients with irritable bowel syndrome. Gastroenterology. 2016. Vol. 150. P. 875–887.Böhn L., Störsrud S., Törnblom H., Bengtsson U., Simrén M. Self-reported food-related gastrointestinal symptoms in IBS are common and associated with more severe symptoms and reduced quality of life. Am.J. Gastroenterol. 2013. Vol. 108. P. 634–641.Böhn L., Störsrud S., Törnblom H., Bengtsson U., Simrén M. Self-reported food-related gastrointestinal symptoms in IBS are common and associated with more severe symptoms and reduced quality of life. Am.J. Gastroenterol. 2013. Vol. 108. P. 634–641.Sharkey K.A., Wiley J.W. The role of the endocannabinoid system in the brain-gut axis. Gastroenterology. 2016. Vol. 151, No. 2. P. 252–266.Sharkey K.A., Wiley J.W. The role of the endocannabinoid system in the brain-gut axis. Gastroenterology. 2016. Vol. 151, No. 2. P. 252–266.Nent E., Nozaki C., Schmöle A.C., Otte D., Zimmer A. CB2 receptor deletion on myeloid cells enhanced mechanical allodynia in a mouse model of neuropathic pain. Sci. Rep. 2019. Vol. 9. p. 7468.Nent E., Nozaki C., Schmöle A.C., Otte D., Zimmer A. CB2 receptor deletion on myeloid cells enhanced mechanical allodynia in a mouse model of neuropathic pain. Sci. Rep. 2019. Vol. 9. p. 7468.Castro J., Maddern J., Garcia-Caraballo S., Schober G., Lindstrom B., Schmiel S. et al. Sa1078 cannabinoid receptor expression and the effect of Olorinab, a peripherally acting, highly selective, full agonist of the cannabinoid receptor 2 (CB2), in rodents with colitis and chronic visceral hypersensitivity. Gastroenterology. 2020. Vol. 158. No. 6. S269.Castro J., Maddern J., Garcia-Caraballo S., Schober G., Lindstrom B., Schmiel S. et al. Sa1078 cannabinoid receptor expression and the effect of Olorinab, a peripherally acting, highly selective, full agonist of the cannabinoid receptor 2 (CB2), in rodents with colitis and chronic visceral hypersensitivity. Gastroenterology. 2020. Vol. 158. No. 6. S269.El-Salhy M., Hatlebakk J.G., Gilja O.H., Brathen Kristoffersen A., Hausken T. Efficacy of faecal microbiota transplantation for patients with irritable bowel syndrome in a randomised, double-blind, placebo-controlled study. Gut. 2020. Vol. 59, No. 5. P. 859–867.El-Salhy M., Hatlebakk J.G., Gilja O.H., Brathen Kristoffersen A., Hausken T. Efficacy of faecal microbiota transplantation for patients with irritable bowel syndrome in a randomised, double-blind, placebo-controlled study. Gut. 2020. Vol. 59, No. 5. P. 859–867.Winston J., Shenoy M., Medley D., Naniwadekar A., Pasricha P.J. The vanilloid receptor initiates and maintains colonic hypersensitivity induced by neonatal colon irritation in rats. Gastroenterology. 2007. Vol. 132. P. 615–627.Winston J., Shenoy M., Medley D., Naniwadekar A., Pasricha P.J. The vanilloid receptor initiates and maintains colonic hypersensitivity induced by neonatal colon irritation in rats. Gastroenterology. 2007. Vol. 132. P. 615–627.

The authors declare that there are no conflicts of interest present.